GSK to cut jobs while investing £400m in Cambridge: what is behind the shake-up? 

GSK has announced a restructuring programme that combines job cuts, annual savings of £1.9 billion and a £400 million investment in research. Although those decisions may appear contradictory, they form part of the same strategy: reducing costs in some areas while directing more money towards new medicines, specialist skills and faster clinical trials. 

The pharmaceutical company has not yet confirmed how many roles will disappear. It has said, however, that the changes will affect support functions, internal processes and parts of the business where technology can replace or simplify existing work. 

More than 1,000 scientists set to move to Cambridge 

GSK plans to spend £400 million over the next three years, with much of the investment supporting a new research and development centre at the Cambridge Biomedical Campus. 

More than 1,000 scientists currently based in Stevenage are expected to move to the new facility. GSK intends to leave its Stevenage research site by 2029, while continuing to invest in laboratories at Ware. 

Cambridge offers access to universities, hospitals, biotechnology companies and specialist investors. Bringing research teams into the same area could help GSK recruit scientists, build partnerships and move promising treatments through development more quickly. 

A £1.9 billion savings target 

The wider restructuring programme is expected to generate £1.9 billion in annual savings by 2029. GSK estimates that carrying out the changes will cost around £2.4 billion over three years. 

The savings are likely to come from simplifying the organisation, reducing administrative work, improving procurement and using artificial intelligence and automation more widely. Some teams may be combined, while duplicated roles could be removed. 

The effects will therefore vary across the company. Certain scientific and technical jobs may move or expand, while employees in support or administrative positions could face greater uncertainty. 

Why is GSK changing direction? 

The company wants to focus more heavily on cancer treatments, respiratory medicine, immunology, vaccines and HIV. It is also preparing for important HIV medicines to lose patent protection between 2028 and 2030, which could increase competition from cheaper alternatives. 

Money released through the savings programme will be reinvested in research and experimental drugs. GSK is expanding its late-stage clinical trial programme and aims to generate annual sales of more than £40 billion by 2031. 

This is not simply a response to falling revenue. The company reported second-quarter sales of around £8.4 billion. The restructuring is instead designed to change where money is spent and which parts of the business receive the greatest attention. 

Investment can still mean job losses 

GSK’s plans show that a large investment does not always translate into a simple rise in employment. Hundreds of millions of pounds can be spent on laboratories and research while jobs disappear elsewhere in the same organisation. 

The changes may create opportunities for specialists in clinical development, oncology, data science, laboratory research and automation. At the same time, employees whose work can be centralised, combined or automated may be more exposed to cuts. 

The investment strengthens Cambridge’s position as a major life sciences centre, but it also marks the end of an era for GSK’s research operations in Stevenage. The expansion and the redundancies are not separate developments. Together, they reveal how the company intends to compete over the next decade. 

You can explore current opportunities in science, healthcare and other sectors on Jober.uk.